Gene To IND In 12 Months Without Increased Risk

In this webinar we talk about how Lonza’s advanced platform can achieve speed whilst minimizing risks to achieve the optimal program profile for a seamless transition from gene to IND and beyond. To help companies navigate through this uncertainty, de-risk and accelerate their path to IND, Lonza has created the Ibex® Design solution. The program not only guarantees* timelines to supply tox drug product material in 9 month and GMP drug product for phase 1 trials in 12 months, but also delivers a scalable, commercially viable process. Our subject matter experts in cell line, process and drug product development will walk you through the details and supporting data about how the convergence of technological innovations and 30 years of track record can deliver speed without compromise.